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Background: Dendritic cells and their subsets, located at mucosal surfaces, are among the first immune cells to
encounter disseminating pathogens. The cellular restriction factor BST-2/tetherin (also known as CD317 or HM1.24)
potently restricts HIV-1 release by retaining viral particles at the cell surface in many cell types, including primary
cells such as macrophages. However, BST-2/tetherin does not efficiently restrict HIV-1 infection in immature
dendritic cells.
Results: We now report that BST-2/tetherin expression in myeloid (myDC) and monocyte-derived dendritic cells (DC)
can be significantly up-regulated by IFN-α treatment and TLR-4 engagement with LPS. In contrast to HeLa or 293T
cells, infectious HIV-1 release in immature DC and IFN-α–matured DC was only modestly affected in the absence of
Vpu compared to wild-type viruses. Strikingly, immunofluorescence analysis revealed that BST-2/tetherin was excluded
from HIV containing tetraspanin-enriched microdomains (TEMs) in both immature DC and IFN-α–matured DC. In
contrast, in LPS-mediated mature DC, BST-2/tetherin exerted a significant restriction in transfer of HIV-1 infection to
CD4+ T cells. Additionally, LPS, but not IFN-α stimulation of immature DC, leads to a dramatic redistribution of cellular
restriction factors to the TEM as well as at the virological synapse between DC and CD4+ T cells.
Conclusions: In conclusion, we demonstrate that TLR-4 engagement in immature DC significantly up-regulates the
intrinsic antiviral activity of BST-2/tetherin, during cis-infection of CD4+ T cells across the DC/T cell virological synapse.
Manipulating the function and potency of cellular restriction factors such as BST-2/tetherin to HIV-1 infection, has
implications in the design of antiviral therapeutic strategies.
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Dendritic cells (DC) are critical initiators of immune
responses after encountering a pathogen at mucosal sites
[1]. These cells have potent phagocytic and anti-microbial
properties placing them at the interface between innate
and adaptive immunity [2]. Pathogens, such as HIV-1, have
evolved strategies to counteract DC functions and some
DC subtypes, such as myeloid DC (myDC) or Langerhans
cells (LC), have been shown to potently restrict HIV-1 in-
fection in the early events of viral entry due to their
primary endo/phagocytic functions [3-5]. Several add-
itional obstacles to HIV-1 replication in DC and their
subsets have also been identified. Surface receptors,
such as langerin [4], cellular restriction factors includ-
ing SAMHD1 [6,7] and members from the APOBEC3
protein family [8-11] as well as other restriction fac-
tors that remain undefined [12,13] can inhibit HIV-1
in the early stages of entry and replication within DC.
The stage at which LC (DC subtype) activation occurs
is important, as langerin is down-regulated in mature
LC [14,15] while APOBEC-3 levels are increased in
mature DC [10,16]. This shows that restriction in DC
is not static and is highly regulated by the inflamma-
tory environment that can be modulated by the
pathogen. In addition, later steps of HIV-1 replication are
also compromised in DC, mostly in mature cells ([17-19]
and reviewed in [20]). HIV-1 was shown to be able to
circumvent some of these restrictions mainly due to
accessory viral proteins that were able to antagonize
specific cellular restrictive or antiviral activities [21-
23]. Among these, viral protein U (Vpu) was recently
shown to antagonize the antiviral effect of BST-2/
tetherin, an interferon (IFN) inducible protein, able to
tether nascent virions to cellular membranes [24,25].
BST-2/tetherin can inhibit a broad range of enveloped
viruses [24-30].
Vpu is a critical factor for efficient viral release in
several cell types [31,32] (and see an extensive review
in [33]). This capacity is dependent on the interaction
of Vpu with BST-2/tetherin, leading to its cell surface
down-regulation [34-36] and degradation of BST-2/
tetherin in some cell types via a β-TrCP-dependent
mechanism [37-40]. A very elegant model of the mode of
action of BST-2/tetherin was recently proposed, show-
ing that antiviral activity was mainly based on the
structural configuration of the protein, rather than
the primary sequence, leading to incorporation of parallel
homodimers into HIV-1 particles [28]. Furthermore,
super-resolution microscopy studies have established
that 5 to 6 BST-2/tetherin dimers are sufficient to re-
strict HIV-1 budding [41]. However, BST-2/tetherin
restriction seems to be cell type dependent (to some
extent) as DC have been reported as unable to inhibit
replication of HIV-1 in the absence of Vpu [42]. Finally,tetherin is also able to counteract cell-to-cell transfer of
HIV-1 under some circumstances [43,44].
In our study, we report that both human monocyte-
derived dendritic cells (DC) and myeloid DC (myDC)
express BST-2/tetherin constitutively, which can be
highly up-regulated upon IFN-α treatment, as previ-
ously shown in murine DC [45]. We demonstrate that
BST-2/tetherin was dramatically down-regulated from
the cell surface of infected DC and myDC in a Vpu-
dependent manner, but there is no evidence of subsequent
protein degradation. However, while IFN-α pre-treatment
decreased HIV-1 infection of DC in cis, we unexpect-
edly observed that viral release and infectivity were
only slightly affected upon DC infection with vpu-de-
ficient HIV-1 (HIV-ΔVpu). Thus, we compared virion
localization by confocal imaging of DC infected with
HIV-WT and HIV-ΔVpu. While the majority of HIV-
WT and HIV-ΔVpu viruses were stained at the DC
cell surface, we observed a lack of BST-2/tetherin
staining when viruses were localized in intracellular
compartments. We identified these compartments as
the previously reported surface-accessible tetraspanin-
enriched (TEM) compartments [46]. We demonstrate
that HIV-WT and HIV-ΔVpu transfer to CD4+ T
cells, both in trans and in cis, was not affected even
when BST-2/tetherin expression was silenced in DC.
Hence, the fact that no restriction could be observed
upon DC-mediated viral transfer correlated with the
absence of BST-2/tetherin at the virological synapse
upon contact with primary CD4+ T cells. Finally, by im-
posing differential levels of restriction activity in DC,
we could observe that while IFN-α pre-treatment of
DC did not apparently modulate BST-2/tetherin
localization and restriction activity, LPS pre-treatment
induced a significant re-localization of the restriction fac-
tor to the TEM. The observed LPS-mediated BST-2/
tetherin re-localization correlated with its polarization
at the virological synapse formed between DC and
CD4+ T cells, with consequent BST-2/tetherin restric-
tion activity being revealed in DC-mediated HIV-1 trans-
fer in cis to CD4+ T cells.
In conclusion, we have demonstrated that HIV-1
avoids BST-2/tetherin restriction in immature DC, as
well as IFN-α treated DC, on the basis of complex traf-
ficking, despite a seemingly conserved role of Vpu in
these cells. Strikingly, TLR-4 engagement of DC corre-
lated with a significant up-regulation of BST-2/tetherin-
mediated restriction of vpu-deficient HIV-1 both in cis
and in trans. Furthermore, we have shown that TEM
composition is modulated after LPS-mediated DC
maturation with re-localization of BST-2/tetherin to
this domain, which could take part in the restricted
viral transfer to target T cells initiated from infected
mature DC.
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HIV-1 Vpu down-regulates cell surface BST-2/tetherin in
infected DC
BST-2/tetherin cell surface levels were determined by
flow cytometry in DC and myDC infected with HIV-1 in
the presence or absence of Vpu. Due to a potent post-
entry restriction block, DC were particularly refractory
per se to productive HIV-1 infection even when Vpu was
absent (Figure 1A, upper panels), while myDC appeared
less refractory to productive infection (Additional file 1:
Figure S1A, upper panels). Although, quantification of a
significant down-regulation of Vpu-mediated BST-2/
tetherin at the cell surface of HIV-infected cells from
different donors was possible, the low level of infection
renders qualitative measurements more challenging.
Therefore, we took benefit from the recently discovered
ability of Vpx to circumvent post-entry restriction block in
DC [6,7,12] in order to increase levels of HIV-1 infection.
Co-transduction of DC with pseudotyped GFP-expressing
HIV and Vpx-expressing SIV-derived lentivectors led to
robust GFP expression at day 2 and 5 post-infection as
shown by FACS analysis (Additional file 1: Figure S2).
Given the ability of Vpx to confer susceptibility of DC and
myDC to HIV infection, we investigated whether Vpu
could down-regulate the level of BST-2/tetherin at the sur-
face of both cell types. DC were left uninfected or infected
with X4-tropic full length HIV-1virus (HIV-WT) or a Vpu
deleted version (HIV-ΔVpu), concomitantly with the
transduction of Vpx-expressing SIV-derived lentivectors.
Two days after HIV-WT infection, FACS analysis of HIV-
Gag positive cells demonstrated a significant cell surface
BST-2/tetherin down-regulation of around 60% in DC
(Figure 1A, lower panels) and 70% in myDC (Additional
file 1: Figure S1A, lower panels) compared to non-infected
(NI) cells. This effect was Vpu-dependent since down-
regulation was negligible when cells were infected with
HIV-ΔVpu (Figure 1A and Additional file 1: S1A).
BST-2/tetherin was previously shown to greatly reduce
viral release and infectivity from cells infected with Vpu-
deficient viruses [24,25,47]. To investigate if BST-2/
tetherin could also restrict HIV-1 replication in DC sub-
types, we analyzed the release of infectious viruses from
supernatants of cells infected with either HIV-WT or
HIV-ΔVpu viruses. We then analyzed the yield of infec-
tious virions using TZM-bl reporter cells and observed
that the absence of Vpu slightly, but significantly,
decreased viral infectivity by 2 fold in DC. Although viral
infectivity was also lower in myDC infected with HIV-
ΔVpu, this decrease was not significant (Figure 1B).
Overall, the observed decrease of viral infectivity and
viral release from HIV-ΔVpu infected DC was not com-
parable to the 12 fold decrease of viral infectivity
observed in supernatants from HIV-ΔVpu infected HeLa
cells (Figure 1C). These data strongly suggest that BST-2/tetherin in DC and myDC was far from being as restrictive
as observed in HIV-ΔVpu infected HeLa cells where al-
most 93% of HIV-ΔVpu release was blocked.
The relative lack of significant BST-2/tetherin restric-
tion activity in DC was confirmed by anti-HIV-Gag
immunoblot of cell lysates and supernatants obtained
from HIV-WT and HIV-ΔVpu infected cells showing
comparable levels of infection (Figure 1D). The same
results were obtained with infected myDC (Additional
file 1: Figure S1B). Additionally, Vpu-mediated BST-2/
tetherin degradation, reported in other cell types [37,38,48],
was not demonstrated in lysates of either DC sub-
types even with high levels of infection (Figure 1D and
Additional file 1: Figure S1B).
LPS-mediated DC maturation induces BST-2/tetherin
clustering and potently inhibits HIV-1 replication
BST-2/tetherin expression, whether constitutive or IFN-
induced, has been well-characterized in some cell types
[24,25] and even in primary immune cells [49]. However,
there is still limited characterization of BST-2/tetherin
expression and function in primary and in vitro derived
myeloid DC (myDC). Thus, we first analyzed surface
(non-permeabilized) and total (permeabilized) BST-2/
tetherin expression levels in non-treated (NT), IFN-α or
LPS treated DC compared to IFN-α-treated 293T cells by
FACS. Indeed, 293T cells are an appropriate control for
antibody specificity as they are known to lack constitutive
BST-2/tetherin expression (Additional file 1: Figure S3A
and [24]). As expected, BST-2/tetherin expression levels
were increased in 293T cells treated for 24h with IFN-α
(Additional file 1: Figure S3A). As shown, DC expressed
constitutive levels of BST-2/tetherin that were significantly
up-regulated upon IFN-α treatment. LPS appeared to
down-regulate BST-2/tetherin cell surface levels while in-
creasing global expression (Additional file 1: Figure S3A).
The effect of IFNα- and LPS-mediated up-regulation of
BST-2/tetherin in DC and 293T cells was confirmed by
Western blotting (Additional file 1: Figure S3B). Of note, a
specific smear of BST-2/tetherin at 80-90KDa appeared in
IFN-α treated cells but was barely detected in LPS-treated
DC (Additional file 1: Figure S3A). This pattern would fit
with the presence of highly glycosylated forms of BST-2/
tetherin, thus correlating with an increased surface expres-
sion upon IFN-α treatment. As a control, we used HeLa
cells that constitutively express highly glycosylated forms
of BST-2/tetherin (Additional file 1: Figure S3B).
We then compared HIV-WT and HIV-ΔVpu infection
rates in DC pre-treated with IFN-α or LPS. After 3 days
of infection with both viral strains, we observed a similar
~2 fold reduction of intracellular HIV-Gag staining in
IFN-α- and LPS- treated DC compared to non-treated
cells (Figure 2A). Pre-treatment with IFN-α or LPS
decreased rates of infection in DC [11] but did not alter
Figure 1 Vpu-dependent BST-2/tetherin cell surface down-regulation but lack of BST-2/tetherin restriction activity in DC. (A). 2 × 105
DC (A, upper panel) and Vpx-transduced DC (A, lower panel) were infected or not (NI) with HIV-WT or HIV-ΔVpu viruses. Infection of DC was
scored by FACS analysis of BST-2/tetherin+/p24gag+ cells, three days post-infection. Percentage of cell surface BST-2/tetherin+ in infected DC from
7 independent experiments was calculated (right graph panels). (B) TZM-bl cells were incubated for 48 hours with 1/10 volume of supernatant
from HIV-WT or HIV-ΔVpu infected DC or myDC harvested three days post-infection. Infectious units (IU/ml) were quantified using the β-gal assay
obtained from 5 and 3 experiments in DC and myDC respectively. (C) Similar experiments (as above) were performed with supernatant obtained
from HIV-WT or HIV-ΔVpu infected Hela cells (results from duplicate experiments). Error bars represent the mean ± SD of indicated experiment
numbers. (D) Lysates and supernatants of uninfected (NI), HIV-WT or HIV-ΔVpu infected DC were subjected to immunoblotting with anti-Gag
and anti-BST-2. The presence of Vpu was assessed by immunoblotting with anti-Vpu and anti-actin served as loading control.
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was comparable to control infected cells (Figure 2A).
DC were challenged with a HIV-1 fusion defective mu-
tant (HIV-F522Y), which prevents transmission of HIV
to target cells even with a similar viral input and therefore
serves as an important control for further DC-mediated
HIV-1 transfer experiments (Figure 2A). Surprisingly,
IFN-α pre-treatment only modestly affected HIV-ΔVpu
viral release and infectivity levels compared to HIV-WT
(Figure 2B and 2C). In sharp contrast, LPS pre-treatment
was shown to impose a 10-fold decrease of HIV-WT in-
fectivity yields (Figure 2B) and a 2-fold decrease of viral
release (Figure 2C). Strikingly, viral release and infectivity
upon HIV-ΔVpu challenge were decreased by 2 fold and
3.5 fold, respectively, after LPS pre-treatment when com-
pared to HIV-WT (Figure 2B, 2C and 2D). These data
demonstrate that LPS-driven DC maturation can induce a
significantly more potent restriction to HIV-ΔVpu infec-
tion than IFN-α treatment.
To investigate the differential restriction of HIV-ΔVpu
infection in DC after IFN-α or LPS, we analyzed BST-2/
tetherin localization in infected DC. We observed that,
while BST-2/tetherin was excluded from CD81-enriched
domains in IFN-α pre-treated DC as seen in non-treated
cells, LPS leads to a dramatic relocalization of the restric-
tion factor to an intracellular CD81-enriched compartment
(Figure 3A and 3B). After HIV challenge, BST-2/tetherin
was also relocalized to the HIV-containing tetraspanin-
enriched microdomain (TEM) in LPS-treated DC, while it
remained excluded from this compartment in non-treated
and IFN-α pre-treated infected DC (Figure 3A and 3B).
These results highlighted a potential role of BST-2/tetherin
on HIV-1 replication in LPS-mediated mature DC and
prompted us to analyze if this could have any conse-
quences on mature DC-mediated transfer of cis infection
to CD4+ T cells compared to non-treated and IFN-α
treated DC.
BST-2/tetherin localization at the virological synapse and
impact on DC-mediated HIV-1 transfer to CD4+ T Cells
As DC play a critical role in virus dissemination by cap-
turing HIV-1 and transferring the virus to T cells in a
biphasic mode ([20,50] and reviewed in [20]), we first
studied the effect of BST-2/tetherin in the initial transfer
phase, or trans infectious mode. DC were left untreated
or treated with IFN-α for 24h and challenged with HIV-
1 for 6 hours. Upon DC-mediated HIV-1 capture, cells
were co-incubated for 3–4 days with autologous CD4+ T
cells pre-treated with indinavir to stop replication. We
observed that IFN-α and LPS treatments did not impact
significantly on DC-mediated transfer of captured HIV-
WT or HIV-ΔVpu (Figure 4A and 4B). These results
were also confirmed with Jurkat T cells used as targets
(Additional file 1: Figure S4). Therefore, we aimed to lookat BST-2/tetherin impact on DC-mediated HIV-1 transfer
in trans by silencing the cellular restriction factor expres-
sion with specific targeted siRNA (siTetherin) compared
to scrambled siRNA (siCtrl)-transfected DC (Figure 4C).
As shown, HIV-1 transfer in trans from siTetherin-DC
was similar to viral transfer from siCtrl-DC upon HIV-
WT or HIV-ΔVpu capture (Figure 4A and 4B). As a con-
trol, we challenged DC with HIV-F522Y (introduced in
Figure 2A) to rule out any HIV-1 transfer potentially
derived from the initial viral input (Figure 4A).
The potent restrictive activity of BST-2/tetherin against
HIV-1 was shown to take place during late events of viral
replication when budding occurs at the plasma membrane
[24,25]. However, the potential impact of BST-2/tetherin
on cell-to-cell viral spread appears controversial in recent
reports analyzing HIV-1 transfer from T cell-to-T cell
[43,51,52]. It was thus important to establish if BST-2/
tetherin had a role in viral transfer to CD4+ T cells after
HIV-1 replication in DC. Untreated, IFN-α and LPS-
treated DC were infected for three days with HIV-WT or
HIV-ΔVpu and then co-cultured with Indinavir-treated
autologous CD4+ T cells for 3 additional days. FACS ana-
lysis of intracellular HIV-Gag in CD3+ cells revealed no
major differences in the transfer rates of either virus
whether the infection came from NT DC or IFN-α
pre-treated DC (Figure 5A and 5B) despite comparable
infection input (data not shown). Of note, a partial effect
of IFN-α on HIV-1 transfer upon replication was also
observed in a T cell-to-T cell model [53]. In each experi-
ment, the fusion mutant viral strain (VSV-G pseudo-
typed-HIV-F522Y) that is able to complete only the first
replication cycle, was used as a control to exclude any
potential T cell infection coming from the initial viral
input (Figure 5A). While mature DC were shown to
efficiently capture and transfer HIV-1 in trans to tar-
get cells, HIV-1 replication is known to be potently
altered in these cells thus limiting in-cis infection of
CD4+ target T cells [18,50]. Indeed, we observed that
LPS matured DC-mediated HIV-1 transfer in cis to
CD4+ T cells was significantly reduced but with an
even more pronounced deficit when mature DC were
infected with HIV-ΔVpu (Figure 5C).
In the reported T cell-to-T cell transfer assays of HIV-
1, BST-2/tetherin was shown to localize to, or even be
enriched within, the virological synapse (VS) in order to
inhibit or inversely potentiate Vpu-defective virus trans-
fer respectively [43,51]. In order to explain the effect of
BST-2/tetherin activity on viral transfer in cis, we then
analyzed its localization at the interface of infected DC
in contact with autologous CD4+ T cells. When polar-
ized HIV-Gag was observed between T cells and NT or
IFN-α treated DC, BST-2/tetherin was in fact drastically
excluded from cell-to-cell contacts (Figure 6A) in sharp
contrast with the striking enrichment of CD81 at the
Figure 2 LPS-induced BST-2/tetherin restriction activity in HIV-1 infected DC. (A) 2 × 105 DC, previously treated (or not) with IFN-α or LPS,
were left uninfected (NI) or infected for 3 days with HIV-WT, HIV-ΔVpu or HIV-F522Y viruses in parallel with SIV3 (+Vpx) transduction. Infection
rates in DC were scored by FACS analysis of BST-2/tetherin+/p24gag+ cells, three days post-infection. (B) TZM-bl cells were incubated for 48 hours
with 1/10 volume of supernatant from HIV-WT or HIV-ΔVpu infected DC, previously untreated (NT) or treated with IFN-α or LPS, and harvested
three days post-infection. Infectious units (IU/ml) were quantified as above in NT DC and treated DC (from 5 and 3 experiments respectively). (C)
Supernatants from HIV-WT or HIV-ΔVpu infected DC, previously untreated (NT) or treated with IFN-α or LPS, were harvested three days post-infection
and HIV-p24 levels were quantified by ELISA. (D) Graph represents the percentage of HIV-ΔVpu / HIV-WT infectivity ratios from treated DC as indicated
and compared to Hela cells.
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Figure 3 LPS-induced relocalization of BST-2/tetherin in HIV-containing tetraspanin-enriched compartment. (A) Confocal
immunofluorescence analysis of HIV-Gag (green), BST-2/tetherin (red) and CD81 (blue) of DC pre-treated (or not) with IFN-α or LPS and left
uninfected or challenged with HIV-WT or HIV-ΔVpu for 3 days. Data are representative of four independent experiments. Scale bars correspond to
5 μm. (B) Graphs represent the quantification of BST-2/tetherin and CD81 co-localisation with HIV-Gag from at least 24 cells per condition from 3
independent experiments.
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(5-18%) of total membrane BST-2/tetherin was found
to localize at the VS established between HIV-WT or
HIV-ΔVpu infected NT or IFN-α treated DC (Figure 6B)
whereas around 60% of membrane CD81 tetraspanin was
found to be polarized at the DC-T VS (Additional file 1:
Figure S5B). Strikingly, we found about 50-60% of the
membrane BST-2/tetherin to be relocalized at the VS
formed between infected LPS matured DC and CD4+ T
cells, in parallel with an enhanced CD81 enrichment
(Figure 6B and Additional file 1: Figure S5B).Conclusions
BST-2/tetherin was demonstrated to be a potent restric-
tion factor for enveloped virus release [24-27,29,30].
However, its role in cell-to-cell viral transfer is still un-
clear. In vivo viral restriction activity of BST-2/tetherin
was demonstrated in a report showing that tetherin-
deficient mice could not inhibit Moloney murine
leukemia virus (Mo-MLV) replication and disease pro-
gression [54]. While this restriction factor is constitu-
tively expressed at low levels at the surface of some
hematopoietic cells, its antiviral action is only unveiled
Figure 4 BST-2/tetherin impact on DC-mediated HIV-1 transfer in trans. (A). 1 × 105 DC, previously transfected (or not) with siTetherin or si
Control (siCtr) for 48 hours, were left untreated (NT) or treated with IFN-α or LPS and challenged for six hours with 200 ng P24gag of HIV-ΔVpu or
HIVF522Y viruses. DC, extensively washed, were then co-cultured with 1 × 105 autologous CD4+ T cells pre-treated 30 minutes before co-culture with
Indinavir. HIV-1 transfer on autologous CD4+ T cells was scored by FACS analysis of CD3+p24gag+FITC cells, four days post-transfer. Data shown are
representative of three independent experiments. (B). Fold enhancement of HIVWT and HIV-ΔVpu transfer in CD3+/CD4+ T cells. A value of 1 was
assigned to the percentage of transfer in the non-treated (HIV) conditions. Error bars indicate standard error mean (SEM). Data are representative of
four different experiments. P-values of paired bilateral Student Test were not significant (p>0.18). (C). DC were transfected with siTetherin or siControl
(siCtr) and left untreated (NT) or treated with IFN-α for 24 hours. Tetherin expression was analyzed by western blot. Data are
representative of four experiments.
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critical for the antiretroviral activity of IFN-α in vivo
[54]. This agrees with a recent report showing that
induction of BST-2/tetherin expression after pegylated
IFN-α/ribavirin treatment strongly correlated with reduc-
tion in HIV-1 load and with the antiretroviral capacity of
IFN-α in vivo [55]. As an inflammatory environment is a
pre-requisite to increase both BST-2/tetherin expression
and restriction activity in specific cell types, we aimed toinvestigate the potential restriction activity of BST-2/
tetherin in different DC subsets while modulating their
maturational state with IFN-α or LPS. One of the limiting
steps to studying HIV-1 infection in DC from myeloid ori-
gin is the fact that these cells are quite refractory to HIV-1
infection, more particularly when cells are matured, due
to potent post-entry restriction blocks [6,7,10]. Taking
advantage of the recent characterization of SAMHD1-
mediated restriction in myeloid DC [6,7], we used
Figure 5 BST-2/tetherin-mediated restriction on cis-infection from matured infected DC. (A) 1 × 105 DC, previously treated (or not) with
IFN-α or LPS, were left uninfected (NI) or infected for 3 days with HIV-WT, HIV-ΔVpu or HIVF522Y viruses in parallel with Vpx-VLPs transduction.
Cells were then co-cultured with 1 × 105 autologous CD4+T lymphocytes. HIV-1 transfer on T lymphocytes was scored by FACS analysis of
CD3+p24gag+FITC cells, three days post-transfer. (B) Quantification of viral transfer from treated DC as indicated was obtained from 5 different
experiments for NT and IFN-α conditions and 3 independent experiments for LPS condition. (C) Percentage of DC-mediated HIV-ΔVpu transfer for
each condition was then measured and depicted in the lower graph.
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this restriction block and to allow higher levels of HIV-1
infection to be reached in DC from myeloid origin.
This provided a more accurate way to measure the effects
of BST-2/tetherin in this cell type. This setting did not
compromise either DC maturation or the response to
IFN-α or LPS treatment but allowed higher levels of
HIV-1 infection, as previously shown [56] and as evi-
denced by BST-2/tetherin and RIG-I up-regulation.Interestingly, BST-2/tetherin up-regulation was recently
proposed to occur in most immune cells from patients in
the acute phase of HIV-1 infection [57] as well as in sim-
ian CD4+ T cells upon SIV infection [58]. In fact, and in
agreement with a recent report from Coleman et al. [42],
we found that, although HIV-1 infection led to BST-2/
tetherin up-regulation, viral spread from DC was not effi-
ciently restricted in the presence of BST-2/tetherin, even
after removal of the SAMHD1-mediated post-entry
Figure 6 BST-2/tetherin polarization and enrichment at the Virological Synapse. (A) Confocal immunofluorescence analysis of HIV-Gag
(green) and BST-2/tetherin (red) upon DC/T cell contacts from experiments above. (B) Virological Synapse (VS) signal intensity / total signal was
then quantified from 3 different experiments (n= 15 for each condition) for each marker.
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while constitutive BST-2/tetherin expression could be
detected at the surface of both monocyte-derived DC and
myDC, its expression was greatly up-regulated after IFN-α
or LPS treatment of both DC subsets. When primary DC
subsets were challenged with HIV-WT and HIV-ΔVpu,
we observed that BST-2/tetherin surface expression could
also be decreased in a Vpu-dependent manner as previ-
ously reported for other cells [24,25,28]. Surprisingly, how-
ever, Vpu-mediated down-regulation of BST-2/tetherin
from the cell surface did not correlate with significant
enhancement of viral release suggesting that the lack of
tetherin-mediated HIV-1 restriction might be Vpu-inde-
pendent. Hence, BST-2/tetherin down-regulation at thecell surface of both DC subsets was not always followed by
its degradation, as previously observed in other cells
[37,38,48]. Overall, these results demonstrated that the ab-
sence of Vpu did not result in significant alteration of
HIV-1 replication in these cells and thus precluded BST-2/
tetherin-mediated restriction activity against HIV-1 in
primary DC.
Interestingly, some recent reports have shown that
BST-2/tetherin expression is up-regulated after stimula-
tion with TLR agonists [42,57,59,60], which reinforces
the idea that this cellular restriction factor could be a
critical component of the intrinsic innate immune re-
sponse. We have demonstrated here that, while IFN-α
treatment was unable to efficiently restrict DC-to-T cell
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a much more potent blockade of viral infection and
transfer in-cis toward autologous CD4+ T cells. Strik-
ingly, when LPS-matured DC were challenged with
HIV-ΔVpu, viral replication and transfer were decreased
by more than 4 fold and 2 fold (respectively) compared
to HIV-WT.
As tetherin surface levels were modulated in IFN-α or
LPS-treated cells and given that previously described
results highlighted a more potent restriction of HIV-
ΔVpu in LPS treated DC compared to IFN-α treated
DC, we hypothesized that a potential mechanism of
BST-2/tetherin restriction in DC could rely on its cellu-
lar localization rather than overall expression. Addition-
ally, treatment with IFN-α or a TLR agonist was shown
to differentially modulate DC maturation and immune
function. In comparison to LPS stimulation, IFN-α was
proposed to only partially affect DC maturation [61,62]
while also inhibiting the production of IL-12 and thus
potentially skewing the T helper response [63,64]. How-
ever, IFN-α is considered as a major regulator of the
antiviral response and has been shown to be a potent
inducer of CD8+T cell cross-priming and therefore cri-
tically required to induce DC full maturation upon en-
gagement of a TLR [65-67]. One of the marked differences
between both of these biological compounds in the
process of DC maturation is that, while LPS-driven mat-
uration is followed by a decreased rate of endocytosis,
antigen-processing and a stabilization of MHC-II/peptide
complexes, IFN-α does not alter MHC-II synthesis, anti-
gen processing or endocytosis rates [68,69]. Thus,
vesicular trafficking pathways could behave differently
depending on the applied stimulus to mature DC. In
fact, we observed that BST-2/tetherin was relocalized
to tetraspanin-enriched compartments only after LPS
stimulation. This localization was similar to the HIV-
containing tetraspanin-rich compartment previously
described [46,70,71]. When LPS-matured DC were
infected with HIV-1, we observed that BST-2/tetherin
was co-localized with tetraspanin CD81. In contrast,
BST-2/tetherin did not accumulate significantly with
CD81 in IFN-α matured DC.
The intracellular relocalization of BST-2/tetherin
observed in DC after LPS treatment did not influence
DC-mediated viral transfer in trans toward CD4+ T
cells. This was demonstrated by the comparable data
obtained with DC-mediated HIV-WT and HIV-ΔVpu
transfer of infection to CD4+ T cells. This was also
confirmed when BST-2/tetherin expression was knock-
downed in DC loaded with HIV-1. Of note, LPS pre-
treatment of DC even increased DC-mediated HIV-1
transfer in trans, independently of BST-2/tetherin ex-
pression as reported by Coleman et al. [42]. While in
agreement with the previously described model of increasedHIV-1 transmission by mature DC through trans-infection
[19,42,72-74], our data exclude a BST-2/tetherin effects
during early DC-mediated HIV-1 capture and transfer to
CD4+ T cells.
In contrast, our data with LPS pre-treated DC sug-
gested that tetherin potently restricts DC-mediated cis-
infection of CD4+ T cells. This restriction correlated
with the polarization of BST-2/tetherin into the HIV-1-
containing tetraspanin-enriched compartments which is
part of the trafficking pathway required for DC-T cell
transfer during HIV-1 infection [46]. A plausible hypoth-
esis would be that this virus-containing compartment,
previously thought to be an escape route for HIV-1,
could in fact become an innate antiviral cell host defense
mechanism when fueled with BST-2/tetherin molecules
after LPS-mediated maturation of DC.
In agreement with its restrictive action in LPS-
matured DC-mediated viral transfer in cis, we found
BST-2/tetherin relocalized to the virological synapse
along with HIV-1 and TEM markers. Hence, it appeared
that BST-2/tetherin localization at the virological syn-
apse was further enhanced with HIV-Δvpu infected LPS-
matured DC in contact with CD4+ T cells, which corre-
lated with the increased accumulation of BST-2/tetherin
observed in HIV-1 containing TEM within LPS-matured
DC infected with HIV-Δvpu. These results also suggest
that, while the lack of BST-2/tetherin-mediated HIV-1
restriction observed in DC-mediated trans-infection
appeared to be Vpu-independent, Vpu might indirectly
contribute to overcome BST-2/tetherin antiviral activity
on DC-mediated HIV cis-infection toward CD4+ T
cells. Indeed, in the absence of Vpu, more BST-2/
tetherin molecules from the cell surface are available
when polarised into the HIV-containing compartment
upon LPS treatment, reinforcing the retention of de novo
budding virions and the restriction of vpu-deficient HIV-1
transmission compared to wild-type viruses. However, as
evidenced by our data, the presence of Vpu in infected
DC does not fully overcome BST-2/tetherin antiviral acti-
vity. Interestingly, a recent publication [75] reported that
localisation of BST-2/tetherin to the virus-containing
compartment (VCC) of infected macrophages correlated
with a decreased HIV release and cell-to-cell transmission.
Importantly, this report also suggested that BST-2/tetherin
was essential for VCC formation. If BST-2/tetherin mole-
cules at the cell surface are a major source for the virus-
containing compartment, this could explain the apparent
increased size of the HIV-containing compartment
observed in HIV-ΔVpu infected DC.
As shown here, and as previously reported [42,76],
BST-2/tetherin is expressed at low levels on DC from
myeloid origin but its expression is increased after HIV-
1 infection [57]. Indeed, conditions where cytokines
and/or pathogen associated molecular patterns (PAMPs)
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with the concept of the dysregulated cytokine storm
observed during HIV-1 acute infection (for review see
[77]). Furthermore, this might even be exacerbated du-
ring co-infection events engaging specific TLR pathways.
Surprisingly, however, we found that IFN-α and TLR
agonist treatments were both differentially regulating
BST-2/tetherin intracellular trafficking.
The lack of BST-2/tetherin restriction in IFN-α treated
DC could be due to the complex trafficking pathway
used by HIV-1 in DC for viral assembly and release. In-
deed, in contrast to T cells and some epithelial cell line
models in which viral release occurs mainly at the
plasma membrane, HIV-1 budding and release from DC
and macrophages was shown to take place in complex
compartments connected, at least in part, to the cell sur-
face and enriched in tetraspanins [46,70,78-80]. There-
fore, in conclusion, we demonstrated that the innate
antiviral BST-2/tetherin activity could be modulated
depending on the context of DC maturational state and
inflammatory environment.
Methods
Ethics statement
All patient samples and cell protocols were approved
by the ethical committees of the Universities of Geneva
and Cardiff. Written informed consent was provided by
study participants and validated by the institutional
review board.
Cells and reagents
Primary cells were purified from peripheral blood mono-
nuclear cells (PBMC) of healthy donors by magnetic
bead-mediated selection, according to the manufac-
turer’s instructions (Miltenyi Biotech). Monocytes were
purified with CD14 MicroBeads and cultured for 5 days
in IMDM supplemented with 10% FCS, 100 U/ml peni-
cillin, 100 μg/ml streptomycin, 500 U/ml GM-CSF and
500 U/ml IL4 (Strathman Biotec, Germany) to generate
immature monocyte-derived DC (MDDC), as previously
described [3]. MyDC were purified with a CD1c DC kit
and cultured in IMDM, supplemented with 10% human
serum and 250 U/ml GM-CSF. Resting CD4+T cells were
isolated with a CD4+T cell isolation kit II and cultured
in RPMI 1640 supplemented with 10% FCS, 100 U/ml
penicillin, and 100 μg/ml streptomycin. They were acti-
vated with 5 μg/ml phytohemagglutinin (PHA) for 36
hours and then maintained by adding IL2 (20 U/ml
Roche). 293T human embryonic kidney cells, TZM-bl
cells and HeLa P4-R5 cells (NIH AIDS Research &
Reference Reagent Program) were maintained in supple-
mented DMEM. HIV-p24 was quantified in supernatants
from infected DC using a p24 ELISA kit (SAIC-Frederick,
Maryland, USA). When stated, MDDC were pre-treatedwith 1000 U/ml interferon alpha (IFN-α, Sigma) for 24
hours or 100 ng/ml LPS.
Viral stock production
Viral stocks were generated by transient transfection of
HEK293T cells with plasmids encoding either full-length
X4-tropic HIV-WT (pR9 and pNL4.3) or X4-tropic
vpu-deficient virus (HIV-ΔVpu) (pR9-Δvpu and pNL4.3-
Δvpu) (both plasmid provided by Trono D, EPFL,
Lausanne). VSV-G pseudotyped HIVF522Y was pro-
duced by co-transfection of the MD.G plasmid [81]
containing the vesicular stomatis virus g-glycoprotein
envelope (VSVG) and a plasmid encoding full length
HIV-X4 genome with non fusogenic gp120/gp41 com-
plex [82]. Infectious titers of viral stocks were evalu-
ated by limiting dilution on HeLa P-4.2 cells containing a
β-gal gene under the control of HIV-1 long terminal
repeat (LTR). Physical particles were evaluated by quantifi-
cation of HIV-1 p24gag by ELISA kit (Beckman Coulter,
Paris, France). VSVG-Pseudotyped SIV3 lentivector enco-
ding the Vpx gene [12,83] was obtained by co-transfection
of SIV3+ packaging construct and pMD.G. The physical
titer of SIV3 was quantified by exogenous reverse tran-
scriptase (exo-RT) assay against standards of known
activity.
Antibodies
Rabbit anti-BST2 made by K. Strebel [49] was obtained
through the AIDS Research and Reference Reagent
Program (Division of AIDS, NIAID, NIH, Bethesda, USA)
and was used for immunoblotting and immunofluorescence
assays. Goat anti-actin, HRP conjugated horse anti-rabbit
and anti-goat (Bio-Rad) were used for immunoblotting.
Mouse anti-tetherin used for FACS analysis was from
Chugai. Human anti-CD3 and anti-CD81 were from
BD Pharmingen and anti-P24gag FITC (Kc57 FITC) was
from Coulter.
Infection and transfer
MyDC or MDDC (1 × 105 cells) were added to 96-well
plates in 100 μl IMDM for challenge with either HIV-
WT (5 ng p24Gag) or HIV-ΔVpu (50 ng p24Gag) to-
gether with 10000 cpm of Vpx-expressing lentivector.
MyDC and MDDC were washed after 24 hours of infec-
tion and maintained at 37°C for another two days. HIV-1
transfer in cis was done by co-culturing infected MDDC
for three days with 1 × 105 CD4+ T cells pre-treated with
Indinavir (2 μg/ml). DC-mediated HIV-1 transfer in trans
was done as previously described [3].
Flow cytometry
After isolation or differentiation, surface staining of pri-
mary cells were performed as previously described. Pro-
ductive infection of a pool of myDC and MDDC was
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3 days post-infection, using an anti-tetherin antibody as
a surface marker. Cells were then washed, fixed, permea-
bilized and stained with anti-p24gag-FITC and analyzed
on a FACS calibur (Beckton Dickinson). Productive
viral transfer in CD4+T cells was controlled by flow
cytometry analysis of intracellular HIV-Gag+ cells, 3
days post-transfer, using an anti-CD3 antibody as a T
cell surface marker.
Confocal immunofluorescence
Cells were left to adhere on poly-L-lysine treated glass
coverslips for 60 min at 37°C. Cells were then fixed, per-
meabilized and stained with the indicated antibodies
followed by fluorescently labeled secondary antibodies
(Jackson ImmunoResearch Laboratories, West Grove,
PA). Staining of Gag, tetherin and CD81 were done
using anti-Gagp24 KC57-FITC, anti-BST-2 pAb (from
K. Strebel) and anti-CD81 mAb respectively. Confocal mi-
croscopy analysis was carried out on a Zeiss LSM510Meta
using a 63× objective and green, red and far red
fluorescence were acquired sequentially. Quantifica-
tion of tetherin, CD81 and Gag colocalization events
were performed using ImageJ Software (NIH) and
analyzed with excel software (Microsoft).
RNA interference in MDDC
MDDC (8 × 105 cells) were plated per well (24-well
plate) and transfected twice with 600 nM of a pooled
siRNA targeting BST-2/tetherin (siBST2) (ON-TARGET-
plus SMARTpool) or with an siRNA control (siGenome
Non-Targeting siRNA #5) (both from Dharmacon) using
HiPerFect reagent (Qiagen), according to the manufac-
turer’s recommendations. A second round of transfec-
tion was performed 24 hours later. After 72 hours,
expression knockdown was checked by Western blotting
followed by densitometry analysis (Quantity One; Bio-
Rad Laboratories), and the cells were subsequently used
for infection assays.
Statistical analysis
Significant differences between groups were calculated
using the Student’s T test (P-values < 0.05 or <0.005
were considered significant and marked with (*) or (**)
respectively).
Additional file
Additional file 1: Figure S1. Shows the same type of experiment as in
Figure 1 but using primary myeloid DC (myDC) isolated from blood.
Figure S2. Shows the infection level in DC at 2 and 5 dpi from cells
challenged with HIV-GFP concomitantly with VLP-Vpx transduction. Figure
S3. Shows the expression of BST-2/tetherin by FACS analysis (S2A) or
immunoblotting (S2B) in lysates obtained from DC left untreated or treated
with IFN-α or LPS. Comparison was made against tetherin level ofexpression in IFN-α-treated 293T cells or untreated Hela cells. Figure S4.
Shows a representative FACS analysis similar to Figure 4 but with a CD4+
Jurkat T cell line as target cells. Figure S5. Shows confocal
immunofluorescence data from Figure 6 but staining for HIV-Gag and CD81.
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